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Adult neurogenesis in intellectual disabilities
Manuela Allegra and Matteo Caleo
In mammals, new neurons are continuously 
produced in two specific neurogenic niches, the 
subventricular zone (SVZ) and the subgranular zone 
(SGZ) in the dentate gyrus (DG) of the hippocampus. 
Adult neurogenesis recapitulates some of the key events 
of brain development including proliferation of neuronal 
progenitors, migration and morphological maturation of 
newly generated cells, and functional integration into brain 
networks. In the SGZ, neural progenitors differentiate 
into dentate granule cells (DGCs), which elaborate 
their dendritic arbor into the molecular layer and extend 
axons to innervate target cells in the CA3 region. To be 
integrated, adult born neurons start to form afferent and 
efferent connections, and this process of synaptogenesis 
is under the control of several local and environmental 
factors. During maturation of their physiology and 
connectivity, the newborn neurons exhibit increased 
excitability and enhanced synaptic plasticity. Due to their 
role in hippocampal plasticity, the adult born cells may 
affect hippocampus-dependent learning and memory. 
Recent studies have highlighted a crucial role for adult 
neurogenesis in the acquisition/forgetting of memories and 
in the discrimination of spatial and contextual information 
[1].
It is well recognized that adult neurogenesis is 
affected in various neurological diseases associated with 
cognitive impairments, such as intellectual disabilities 
(ID), including Rett, Fragile X and Down syndromes. ID 
is a complex disease of the central nervous system (CNS) 
whose pathophysiology is not completely understood and 
no effective cures are available to date.
Oligophrenin-1 (Ophn1) gene, located on X 
chromosome, encodes for a RhoGTPase-activating 
protein (RhoGAP) whose mutations are involved in the 
etiology of X-linked intellectual disability (XLID). Ophn1 
is expressed in the whole brain during development and 
in adulthood. At the cellular level, Ophn1 is expressed 
in both glial and neuronal cells where it colocalizes with 
actin. Due to its interaction with actin, Ophn1 participates 
in several neuronal developmental processes, including 
dendrite and axon growth, axon guidance, synapse 
formation and cell migration [2]. Ophn1 has both a pre- 
and post-synaptic localization, influencing dendritic spine 
morphogenesis and synaptic function and plasticity [3, 
4]. At the electrophysiological level, the loss of function 
of Ophn1 leads to impairments of both excitatory 
and inhibitory synaptic transmission. Ophn1 is a key 
negative regulator of RhoGTPases, a family of molecules 
(including RhoA, Rac and Cdc42) that orchestrate various 
pathways and transduce signals from the extracellular 
environment to the actin cytoskeleton. 
In a recent manuscript [5], we have examined the 
impact of Ophn1 deficiency on neuronal maturation 
by following the process of adult neurogenesis in the 
DG. Using Ophn1 knock-out (KO) mice [4], we found 
significant deficits in the morphological maturation and 
survival of newborn neurons in the DG. Specifically, 
Ophn1-deficient newborn neurons showed alterations in 
axon extension and dendritic maturation [5]. In particular, 
the aberrant axon formation in Ophn1 KO animals, leading 
to altered synaptic connectivity, supports the hypothesis 
that IDs are characterized by circuit impairments due 
to morphological or wiring alterations during neuronal 
development. Moreover, we also found an immature 
phenotype of dendritic spines, consistent with recent 
findings demonstrating that thin, filopodia-like dendritic 
spines are increased in animals lacking Ophn1 [6].
Ophn1 loss of function results in persistent activation 
of RhoGTPases and consequent hyperstimulation of the 
RhoA/ROCK pathway and high levels of PKA activity. 
Based on previous data [7], we used the ROCK/PKA 
inhibitor fasudil, a drug already approved for clinical use 
in Japan and China, as a pharmacological approach to 
treat the impairments associated with Ophn1 deficiency. 
We found that chronic fasudil treatment reversed at least 
some of the pathological alterations of adult hippocampal 
neurogenesis in Ophn1 KO mice. While the deficits 
in axon extension were not affected by the treatment, 
fasudil completely rescued the dendritic spine deficit 
and enhanced the long-term survival of newly generated 
neurons. Similar rescue effects have been reported in the 
context of olfactory bulb neurogenesis [6].
One fundamental question in these studies is 
whether the normalization of adult neurogenesis improves 
cognitive functions. Our data [5] and those of Redolfi et al. 
[6] clearly demonstrate that counteracting the unchecked 
up-regulation of ROCK/PKA signalling by fasudil 
treatment rescues adult neurogenesis. Parallel experiments 
have shown that fasudil treatment normalizes performance 
in specific hippocampus-related behavioural tasks [8], 
highlighting the idea that adult neurogenesis could be a 
potential pharmacological target for cognitive impairments 
associated with ID.
Altogether, the data described above indicate 
that adult neurogenesis allows a precise dissection 
of alterations of neuronal maturation in IDs, and the 
experimental validation of novel therapeutic strategies.
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